FDA approves Replimune melanoma drug previously rejected twice
Reversal, capping a tumultuous saga, is a big win for the biotech company, patient advocates
Adobe
By Elaine Chen
Aug. 6, 2026
Chen, a national biotech reporter, is the co-author of The Readout, a newsletter about the business, science, and politics of biotech.
Elaine’s stories explore the boom in new obesity treatments, new drug payment models, the ways companies are affected by FDA changes, and the emerging psychedelics drug sector. She co-writes The Readout newsletter, and co-hosts STAT’s weekly biotech podcast, The Readout Loud. You can reach Elaine on Signal at elaineywchen.70.
The Food and Drug Administration has cleared Replimune’s treatment for advanced melanoma, dealing the biotech a major win after a tumultuous saga of trying to seek approval for the controversial treatment.
The FDA’s decision to grant accelerated approval to the drug, which is called RP1 and will be marketed as Tudriqev, came after its advisers last week voted in support of the treatment. Even though FDA staff expressed concerns about the design and conduct of Replimune’s key trial, advisers ultimately believed there was a large enough signal of efficacy and that patients are in urgent need of new treatments.
Advertisement
The list price of Tudriqev will be $450,000 per course of therapy before customary rebates and discounts, Replimune said.
STAT+ Exclusive Story
Already have an account? Log in
This article is exclusive to STAT+ subscribers
Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.
Already have an account? Log in
Individual plans
Group plans
Monthly
$39
Totals $468 per year
Totals $468 per year
Starter
$30
for 3 months, then $399/year
Then $399/year
Annual
$399
Save 15%
Save 15%
11+ Users
Custom
Savings start at 25%!
Request A Quote Request A Quote
Savings start at 25%!
2-10 Users
$300
Annually per user
$300 Annually per user
To read the rest of this story subscribe to STAT+.
biotechnology, Cancer, drug development, FDA, Pharmaceuticals, STAT+
Submit a correction request Reprints
National Biotech Reporter
Elaine’s stories explore the boom in new obesity treatments, new drug payment models, the ways companies are affected by FDA changes, and the emerging psychedelics drug sector. She co-writes The Readout newsletter, and co-hosts STAT’s weekly biotech podcast, The Readout Loud. You can reach Elaine on Signal at elaineywchen.70.
Newsletter
Your morning rundown of the science, politics, and money driving biotech today
Please enter a valid email address.Sign Up
Your data will be processed in accordance with our Privacy Policy and Terms of Service. You may opt out of receiving STAT communications at any time.
Recommended
Biotech
BiotechAugust 6, 2026
STAT Plus: Study reveals new role for tau, a top target for Alzheimer’s drug development
The Readout
The ReadoutAugust 6, 2026
STAT Plus: Two FDA approvals — a new drug and a new vaccine
First Opinion
First OpinionAugust 6, 2026
One year since Kennedy canceled mRNA vaccine projects, science shows how wrong he was
Adam's Biotech Scorecard
Adam's Biotech ScorecardAugust 6, 2026
STAT Plus: Biotech’s next big bet: A Tenax study of a heart failure treatment
Biotech
BiotechAugust 6, 2026